Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Hydration is an important part of preventing and treating sickle cell crises, writes columnist Oluwatosin Adesoye, who shares ...
Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Understanding Sickle Cell Anemia and the Need for Early DiagnosisSickle cell anemia is a genetic blood disorder caused by a ...
High bilirubin levels increase the risk of developing bilirubin gallstones—a type of gallstone more prevalent in Sickle Cell ...
New Vision on MSN12d
Breakthrough sickle cell drug causes excitementA groundbreaking sickle cell disease treatment has been approved for use in the UK's National Health Service (NHS). The treatment offers patients with severe forms of the condition hope for a ...
In this article, we explore the experiences of sickle cell patients in emergency care and the ways they can advocate for themselves ...
There is no evidence to support physical exertion without rhabdomyolysis or heat injury causing sudden death in individuals with sickle cell trait (SCT), nor is there evidence that SCT causes acute ...
New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback